Disease
|
Drug Name(s)
|
Company
|
Status/
Time Frame
|
|
AAT deficiency, congenital
|
à1-antitrypsin
|
PPL Therapeutics plc
|
P III planned
|
|
Acute respiratory distress syndrome
|
Surfaxin
|
Discovery Laboratories Inc.
KL4 surfactant
|
P II/III
|
|
AIDS-related cachexia
|
Thalomid
thalidomide
|
Celgene Corp.
|
NDA filing planned
|
|
Allergies and autoimmune disorders
|
oral tolerance regimen
|
Oraltol Ltd.
|
R&D
Cortecs plc
|
|
Alzheimer's disease
|
galantamine
|
Janssen Pharmaceutica
Shire Pharmaceuticals Group
|
P III
|
|
Alzheimer's disease
|
SIB-1553A
|
Sibia Neurosciences Inc.
|
P I
|
|
Alzheimer's disease; type II diabetes
|
PTI-00703
|
Proteotech Inc.
Univ. of Washington
|
R&D
|
|
Angiogenesis in cancer, diabetes, restenosis and atherosclerosis
|
PD 166866
FGF-1 tyrosine kinase inhibitor
|
Parke-Davis, Warner-Lambert
|
R&D
|
|
Anxiety disorders
|
NS2710
|
Neurosearch; Meiji Seika Kaisha Ltd.
Pharmacia & Upjohn
|
P II
|
|
Asthma
|
CP-220,629
|
Pfizer Inc.
|
Preclinical testing
|
|
Atherosclerosis and restenosis
|
Antrin
|
Pharmacyclics Inc.
|
Preclinical testing
|
|
Bone growth, regeneration and repair
|
LMP-1 gene therapy
|
Sofamor Danek Group Inc.
|
Clinical trials planned
|
|
Breast cancer
|
Triab
|
Titan Pharmaceuticals Inc.
|
P II
|
|
Cancer
|
cytoprotective antibodies
|
Immunomedics Inc.
|
R&D
|
|
Cancer
|
p53-targeted program
|
Genome Therapeutics Corp.
|
R&D
|
|
Cancer
|
cytokines
|
Immunex Corp.
American Home Products Corp.
|
Collaboration ended
|
|
Cancer
|
antisense
|
Gilead Sciences Inc.
|
Collaboration ended
|
|
Cancer
|
D2163
MMP-2 inhibitor/angiogenesis inhibitor
|
Bristol-Myers Squibb Co.
Chiroscience Group plc
|
P I
|
|
Cancer
|
NX 211
lurtotecan, liposomal
|
Nexstar Pharmaceuticals Inc.
|
P I planned
early 1999
|
|
Cancer and cardiovascular disease
|
antisense
|
Hybridon Inc.
Searle
|
R&D
|
|
Cancer, asthma, arthritis & infectious diseases
|
transforming growth factor beta inhibitors
|
Glycodesign Inc.
Samuel Lunenfeld Research Inst.
|
R&D
|
|
Cancers positive for Tag-72 antigen
|
MDX-20/G-CSF
|
Medarex Inc.
|
P I/II
|
